Lupin Obtains Exclusive Rights for Innovative͏ G͏LP-1Drug in In͏dia Through͏ Chinese͏ Partnership 

Mumbai, 30 December 2025: Lupin has entered into an exclusive licensing, supply and distribution agreement with Gan & Lee Pharmaceuticals, China-based pharmaceutical company for Bofanglutide, a novel fortnightly GLP-1 receptor agonist for the treatment of type 2 diabetes which broadens Lupin’s diabetes & obesity portfolio in India and adds to its chronic metabolic therapy offerings. 

Exclusive͏ India͏ ͏Pact for͏ Fortnightly GLP-1 Dru͏g as Obesity Crosses 50 ͏Million Cases 

Under the agreement, Lupin has the right to sell Bofanglutide in India. Intended for adults with type 2 diabetes, the injectable therapy given once every two weeks also aids in weight management for those who are overweight or have obesity. Publicly released clinical trial data suggest the weight-loss effect is similar or superior to those of currently marketed weekly G L P-1 therapies, with the benefit of 50% fewer injections. 

India has an estimated 174 million overweight adults, 50 million obese adults and around 90 million adults with diabetes, leading to metabolic diseases becoming one of the largest public health challenges in the country. 

First-in-Class Global Fortnightly GLP-IR Receptor Agonist  

Bofanglutide is being developed as a potential first-in-class global once-fortnightly GLP-1 receptor agonist. Lupin said that the drug reduces blood glucose levels and body weight with safety and tolerability in line with the GLP-1 drug class. The drug is administered for enhancing treatment convenience for long-term treatment of metabolic and chronic diseases. 

Partnership Extends Lu͏pin’s Metabolic Offering After Gan & Lee’s Latin America Deal in November 

Gan & Lee described the India deal as a part of its rapid international expansion after an exclusive agreement in Latin America in November 2025. The Chinese company highlighted that the partnership reinforces its strategic approach to taking its domestically developed biopharmaceuticals, especially in the metabolic disease therapeutic area, to global͏ mark͏͏ets. 

Strategic Emphasis on GLP-1 Class Bolsters Chronic Disease Portfolio  

Lupin’s management said the pact was indicative of its strategic emphasis on the GLP-1 class of drugs and its ambition to expand and innovate therapies for chronic metabolic diseases, especially diabetes and obesity, which are on the rise in India.  

Lupin Limited Share Rises After Partnership Deal Announced 

As on 30 December at 09:46 am IST, Lupin Ltd share price was trading at ₹2,083.70 on the NSE, up by ₹1.60 or 0.077%. The share opened at ₹2,091.70. The company’s market cap stood at ₹95.5 thousand crore, with a p͏rice-to-earnings ratio of 22.15, a 52-w͏eek high of ₹2,4 02.90, and a 52-week low of ₹1,7 95.20. 

References 

• https://www.bseindia.com/stock-share-price/lupin-ltd/lupin/500257/corp-announcements/ 
• https://www.bseindia.com/xml-data/corpfiling/AttachLive/98cb93fb-d2fc-47c2-81d2-5ffb61c4445c.pdf 
• https://www.nseindia.com/get-quote/equity/LUPIN/Lupin-Limited 

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.  

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.  

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations